An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Trial Profile

An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs RG 7828 (Primary) ; Atezolizumab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 14 Sep 2017 Drug Obinutuzumab has been replaced with Atezolizumab. Study design has been changed from parallel design to sequential design. Also trial design has been changed from PK and AR to PK, AR and TU.
    • 14 Sep 2017 Planned number of patients changed from 210 to 390.
    • 14 Sep 2017 Planned End Date changed from 31 Oct 2018 to 31 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top